American Society of Clinical Oncology
ASCO
With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
Sanofi’s experimental breast cancer treatment amcenestrant in combination with Pfizer’s Ibrance is showing promising anti-tumor activity in postmenopausal women with metastatic breast cancer.
BioSpace continues to take a look at some of the data that will be shared at the 2021 ASCO meeting. Here are some of them.
Companies have already begun their announcements of new clinical studies for various treatment settings in preparation for ASCO 2021.
The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.
Numerous biopharmaceutical companies and researchers are presenting research and clinical trial results, and many have been announcing their plans for several weeks.
Bristol Myers Squibb released new data from two clinical trials of Opdivo plus Yervoy-based combinations in non-small cell lung cancer and updated results from the KarMMa trial of ide-cel for multiple myeloma being developed with bluebird bio.
Scot Ebbinghaus, Vice President and Therapeutic Area Head, Oncology Clinical Research, Merck Research Laboratories, took time out ahead of the meeting to discuss three of the company’s clinical trials being presented and the implications for oncology patients and Merck.
ASCO called rare cancer treatments the “advance of the year” in oncology.
As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.
PRESS RELEASES